Good article in FierceBiotech on deal making showing the focus for biotech is completing phase II proof of concept. If IMGN could ever successfully design and complete a phase II...I think they need more horsepower in clinical design. Maybe they rely on CRO's and consultants, but so far the results are unacceptable and require rapid improvement before they have another debacle.
Speaking of debacles. they really know how to step into the shyte on the cc's...too much discussion about side effects, they failed to answer the questions with confidence and left the door open to the short attack. They need better prep to anticipate questions and better control over the analysts, no questions from UBS. Perhaps if they were more shareholder friendly, they might be able to anticipate the hard questions.